Expertise

Prostate cancer

Primære forskningsområder

Mainly company-sponsored research

Aktuel forskning

Ongoing:  

FASE II: A phase 2, open-label, single-arm, efficacy, and safety study of an investigational (Enzalutamide) drug in patients with hormone-naïve prostate cancer - now open-label (role: Principal Investigator)

PRIMORDIUM (2021-): A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients (role: Principal Investigator)

DAROL (2022-): Darolutamide Observational Study in nonmetastatic castration-resistant prostate cancer patients (role: Principal Investigator)

Completed:

BraVac: A Phase 2, Double-Blind, Placebo-Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer (role: Sub-Investigator)

PROSPER: A multinational, phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of an investigational drug in patients with non-metastatic castration-resistant prostate cancer (role: Sub-Investigator)

ARCHES: A multinational, phase 3, randomized, double-blinded, placebo-controlled efficacy and safety study of an investigational drug plus Androgen Deprivation Therapy versus placebo + Androgen Deprivation Therapy in patients with metastatic hormone-sensitive prostate cancer (role: Sub-Investigator)

TERRAIN: A randomized, double-blind, phase 2, efficacy and safety study of an investigational drug versus Bicalutamide in castrate men with metastatic prostate cancer – open-label after (role: Sub-Investigator)

CORAL: A randomized, multi-site, double-blinded, double-dummy, active control, parallel-group, multidose, efficacy, safety, and tolerability phase 3 study of an oral investigational drug versus Morphine in subjects with chronic moderate to severe pain related to cancer (role: Sub-Investigator)

OREXO: A phase 2, randomized, double-blind, placebo-controlled, dose-finding trial using a sublingual investigational drug to alleviate pain associated with a prostate biopsy procedure (role: Sub-Investigator)

GALAHAD: A phase 2 efficacy and safety study of an investigational drug in men with metastatic castration-resistant prostate cancer with DNA-repair anomalies (role: Principal Investigator)

PREVAIL: A multinational, double-blind, randomized, placebo-controlled phase 3 trial of an investigational drug + GnRH therapy in chemotherapy-naïve patients with progressive metastatic CRPC who have failed ADT - now open-label (role: Sub-Investigator)

PROSPECT/PROSTVAC: A randomized, double-blind, phase 3 efficacy trial of an investigational vaccine in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (role: Sub-Investigator)

FERRING:  A prospective observational safety study in patients with advanced prostate cancer treated with a GnRH antagonist or a GnRH agonist (role: Sub-Investigator)

HERO: A multinational phase 3, randomized, open-label, parallel Group study to evaluate the safety and efficacy of an investigational drug in men with advanced prostate cancer (role: Principal Investigator)

PREMISE: A European prospective observational study assessing the efficacy and outcomes associated with AR-targeted treatment in patients with metastatic castration-resistant prostate cancer (role: Sub-Investigator)

Mulige interessekonflikter

Advisory board member for the “Danish Medicines Council” regarding Prostate cancer (2020 - )